Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease

Overview

Journal Antioxidants (Basel)

Date 2024 Nov 27

PMID 39594528

Authors

Emidio Scarpellini

Marialaura Scarcella

Jan F Tack

Giuseppe Guido Maria Scarlata

Michela Zanetti

Ludovico Abenavoli

Affiliations

Soon will be listed here.

Abstract

The gut microbiota constitutes a complex microorganism community that harbors bacteria, viruses, fungi, protozoa, and archaea. The human gut bacterial microbiota has been extensively proven to participate in human metabolism, immunity, and nutrient absorption. Its imbalance, namely "dysbiosis", has been linked to disordered metabolism. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the features of deranged human metabolism and is the leading cause of liver cirrhosis and hepatocellular carcinoma. Thus, there is a pathophysiological link between gut dysbiosis and MASLD. We aimed to review the literature data on the composition of the human bacterial gut microbiota and its dysbiosis in MASLD and describe the concept of the "gut-liver axis". Moreover, we reviewed the approaches for gut microbiota modulation in MASLD treatment. There is consolidated evidence of particular gut dysbiosis associated with MASLD and its stages. The model explaining the relationship between gut microbiota and the liver has a bidirectional organization, explaining the physiopathology of MASLD. Oxidative stress is one of the keystones in the pathophysiology of MASLD and fibrosis generation. There is promising and consolidated evidence for the efficacy of pre- and probiotics in reversing gut dysbiosis in MASLD patients, with therapeutic effects. Few yet encouraging data on fecal microbiota transplantation (FMT) in MASLD are available in the literature. The gut dysbiosis characteristic of MASLD is a key target in its reversal and treatment via diet, pre/probiotics, and FMT treatment. Oxidative stress modulation remains a promising target for MASLD treatment, prevention, and reversal.

References

Endo H, Niioka M, Kobayashi N, Tanaka M, Watanabe T . Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS One. 2013; 8(5):e63388. PMC: 3656030. DOI: 10.1371/journal.pone.0063388. View

Roshanravan N, Mahdavi R, Alizadeh E, Ghavami A, Rahbar Saadat Y, Mesri Alamdari N . The effects of sodium butyrate and inulin supplementation on angiotensin signaling pathway via promotion of abundance in type 2 diabetes; A randomized, double-blind, placebo-controlled trial. J Cardiovasc Thorac Res. 2018; 9(4):183-190. PMC: 5787329. DOI: 10.15171/jcvtr.2017.32. View

Simmons Jr G, Pruitt W, Pruitt K . Diverse roles of SIRT1 in cancer biology and lipid metabolism. Int J Mol Sci. 2015; 16(1):950-65. PMC: 4307284. DOI: 10.3390/ijms16010950. View

Oraphruek P, Chusak C, Ngamukote S, Sawaswong V, Chanchaem P, Payungporn S . Effect of a Multispecies Synbiotic Supplementation on Body Composition, Antioxidant Status, and Gut Microbiomes in Overweight and Obese Subjects: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2023; 15(8). PMC: 10141052. DOI: 10.3390/nu15081863. View

Ridaura V, Faith J, Rey F, Cheng J, Duncan A, Kau A . Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013; 341(6150):1241214. PMC: 3829625. DOI: 10.1126/science.1241214. View

Ahn S, Jang K, Won Jun D, Lee B, Shin K . Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2014; 59(12):2975-82. DOI: 10.1007/s10620-014-3289-x. View

Lee M, Kim C, Kim Y . Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice. Ann Nutr Metab. 2009; 54(2):151-7. DOI: 10.1159/000214834. View

Luo J, Yang H, Song B . Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2019; 21(4):225-245. DOI: 10.1038/s41580-019-0190-7. View

Kounatidis D, Vallianou N, Evangelopoulos A, Vlahodimitris I, Grivakou E, Kotsi E . SGLT-2 Inhibitors and the Inflammasome: What's Next in the 21st Century?. Nutrients. 2023; 15(10). PMC: 10221012. DOI: 10.3390/nu15102294. View

10.

Ferslew B, Xie G, Johnston C, Su M, Stewart P, Jia W . Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci. 2015; 60(11):3318-28. PMC: 4864493. DOI: 10.1007/s10620-015-3776-8. View

11.

Mao Q, Lin B, Zhang W, Zhang Y, Cao Q, Xu M . Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives. Front Pharmacol. 2024; 15:1371574. PMC: 10991717. DOI: 10.3389/fphar.2024.1371574. View

12.

Jiao N, Baker S, Chapa-Rodriguez A, Liu W, Nugent C, Tsompana M . Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2017; 67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307. View

13.

Mehedint M, Zeisel S . Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013; 16(3):339-45. PMC: 3729018. DOI: 10.1097/MCO.0b013e3283600d46. View

14.

Hooper L, Macpherson A . Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. 2010; 10(3):159-69. DOI: 10.1038/nri2710. View

15.

Eslick S, Thompson C, Berthon B, Wood L . Short-chain fatty acids as anti-inflammatory agents in overweight and obesity: a systematic review and meta-analysis. Nutr Rev. 2021; 80(4):838-856. DOI: 10.1093/nutrit/nuab059. View

16.

Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang D . Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. Int J Mol Sci. 2021; 22(10). PMC: 8160908. DOI: 10.3390/ijms22105375. View

17.

Barber T, Hanson P, Weickert M . Metabolic-Associated Fatty Liver Disease and the Gut Microbiota. Endocrinol Metab Clin North Am. 2023; 52(3):485-496. DOI: 10.1016/j.ecl.2023.01.004. View

18.

Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S . Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019; 25(7):1096-1103. PMC: 6699990. DOI: 10.1038/s41591-019-0495-2. View

19.

Dao M, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger E . Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2015; 65(3):426-36. DOI: 10.1136/gutjnl-2014-308778. View

20.

Turnbaugh P, Ley R, Mahowald M, Magrini V, Mardis E, Gordon J . An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027-31. DOI: 10.1038/nature05414. View